Cocrystal Pharma (NASDAQ: COCP) director granted 16,410 options

Rhea-AI Filing Summary

Cocrystal Pharma director Steven D. Rubin reported receiving non-qualified stock options for 16,410 shares of Cocrystal Pharma common stock on January 9, 2026. The options have an exercise price of $1.10 per share and were granted under the company’s 2025 Equity Incentive Plan, approved by the Compensation Committee of the Board.

Half of these options vest and become exercisable on January 9, 2027. The remaining half vests in eight equal quarterly installments starting March 31, 2027, as long as Rubin continues to serve as a director on each vesting date. After this grant, he beneficially owns stock options for 16,410 shares, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rubin Steven D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	16,410	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 16,410 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Steven D

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FL 33137

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)	$1.1	01/09/2026		A		16,410		(1)	01/09/2036	Common Stock	16,410	$0	16,410	D

Explanation of Responses:

1. The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

	/s/ Steven Rubin	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cocrystal Pharma (COCP) report for Steven D. Rubin?

Steven D. Rubin, a director of Cocrystal Pharma, reported the grant of 16,410 non-qualified stock options to purchase Cocrystal Pharma common stock.

What is the exercise price of the options granted to the Cocrystal Pharma director?

The non-qualified stock options granted to the director have an exercise price of $1.10 per share of Cocrystal Pharma common stock.

How do the 16,410 Cocrystal Pharma stock options vest for Steven D. Rubin?

One-half of the 16,410 options vest on January 9, 2027, and the remaining half vests in eight equal quarterly installments starting on March 31, 2027, subject to continued service as a director.

Under which plan were the new Cocrystal Pharma options granted?

The options were granted under Cocrystal Pharma’s 2025 Equity Incentive Plan, using the company’s form of Non-Qualified Stock Option Agreement.

How many Cocrystal Pharma derivative securities does Steven D. Rubin own after this transaction?

Following this grant, Steven D. Rubin beneficially owns 16,410 stock options for Cocrystal Pharma common stock, held directly.

Was the Cocrystal Pharma option grant exempt under Section 16(b)?

Yes. The filing states the non-qualified stock option grant was exempt from Section 16(b) under Rule 16b-3 because it was approved by the Compensation Committee of the Board of Directors.